Zymeworks’ $929m bid for Theravance reshapes its revenue base

Acquisition centres on Yupelri COPD franchise while retaining upside through respiratory and legacy pipeline assets.

Zymeworks is moving decisively beyond its traditional oncology footprint, agreeing to acquire Theravance Biopharma for approximately $929 million in cash, in a deal designed to broaden its revenue base and accelerate its entry into the chronic obstructive pulmonary disease (COPD) market.

The transaction, which includes a contingent value right (CVR) tied to a legacy asset, is expected to close in the second half of 2026.

At the centre of the acquisition is Yupelri (revefenacin), a once-daily nebulised long-acting muscarinic antagonist (LAMA) used for maintenance treatment in COPD. The product is already commercially established in the US and provides the foundation for much of Theravance’s near-term revenue profile.

A commercial asset at the core

Yupelri generated $266.6 million in US sales last year, representing 12% year-on-year growth, and continues to benefit from a relatively protected competitive position.

Theravance holds a 35% revenue-sharing interest in the US product, which is co-promoted with Viatris. Importantly, settlement agreements with generic manufacturers mean competition is not expected until 2039, giving the asset a long runway of protected cash flow.

In addition to current revenues, Theravance is eligible for:

• Up to $125 million in milestone payments tied to US sales performance

• Double-digit tiered royalties on international sales

• Additional milestones linked to ex-US performance of Yupelri
  

The broader respiratory portfolio also includes exposure to GSK’s Trelegy Ellipta, with Theravance expected to receive a $100 million milestone payment in Q1 2027, alongside royalties from other partnered assets such as Vibativ (telavancin).

Strategic shift: from R&D biotech to cash-flow hybrid

For Zymeworks, the deal marks a clear pivot towards a more diversified financial model.

CEO Kenneth Galbraith said the acquisition would "meaningfully expand and diversify future revenue sources" and deliver an immediate uplift in commercial royalty income. The strategy reflects a broader industry trend: biotechs moving to balance high-risk R&D pipelines with stable, partner-driven cash flows.

Rather than relying solely on clinical-stage assets, Zymeworks is now positioning itself as a hybrid business model—combining:

• Established respiratory royalties

• Mid-stage and preclinical R&D programmes

• Externalised non-core assets
  

CVR tied to high-risk neurogenic orthostatic hypotension asset

The deal structure also includes a contingent value right (CVR), giving Theravance shareholders entitlement to 80% of proceeds from any future licensing or divestiture of ampreloxetine over the next 10 years.

The asset has faced repeated clinical setbacks, most recently failing in the Phase III CYPRESS trial in symptomatic neurogenic orthostatic hypotension. Following the failure, Theravance reduced its workforce and began reviewing strategic options for the programme.

Zymeworks will receive the remaining 20% of any future upside.

Portfolio rationalisation and tax assets

Beyond Yupelri and ampreloxetine, the acquisition includes a preclinical immunology and inflammation pipeline. Zymeworks has indicated it intends to externalise these assets, alongside ampreloxetine, rather than advance them internally.

The company will also inherit approximately $2.5 billion in Irish tax attributes, which may be utilised in future to offset taxable income, adding a further layer of long-term financial optionality.

Why this deal matters

This acquisition is less about pipeline transformation and more about balance sheet engineering and revenue stabilisation.

For Zymeworks, Theravance provides:

• Immediate commercial cash flow via a de-risked respiratory asset

• Long-dated exclusivity protection in COPD

• Milestone and royalty upside from adjacent respiratory franchises

• Optionality from legacy and preclinical assets via externalisation
  

In a sector where many biotechs remain heavily dependent on binary clinical outcomes, this deal signals a shift towards durable income streams layered onto traditional drug development models.

If executed successfully, Zymeworks will emerge with a more balanced profile: part R&D innovator, part royalty-driven commercial operator—anchored by one of the more resilient assets in the COPD space.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com